Purepath Lab & Therapeutics, LLC

Purepath Lab & Therapeutics, LLC was paid $118K by Medicaid between Jul 2022 and Jul 2024, across 22 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 58% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#141 of 436

Median peer was paid$17K

This provider vs. median6.8×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2022	5,489	$62K
2023	6,367	$55K
2024incomplete	97	$755.14

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	58%	2,346	1,666	$69K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	19%	2,346	1,666	$23K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	8.9%	456	420	$11K
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	6.0%	2,344	1,664	$7K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	2.6%	1,080	1,068	$3K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	1.2%	68	68	$1K
87631		<1%	203	182	$1K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	<1%	376	277	$582.43
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	332	276	$309.58
87640		<1%	330	274	$309.58
87500		<1%	333	277	$309.58
87653		<1%	332	276	$309.58

10 more codes

87641		<1%	332	$309.58
87541		<1%	220	$280.10
87581		<1%	222	$280.10
87486		<1%	222	$280.10
87498		<1%	222	$280.10
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	0%	16	$0.00
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	0%	84	$0.00
87150		0%	16	$0.00
87481		0%	57	$0.00
81002		0%	16	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialCHAUDHARY, HEMRAJ (OWNER)